What is the recommended naltrexone regimen for treating methamphetamine use disorder in an adult who is not taking opioid analgesics or opioid agonist therapy?

Naltrexone for Methamphetamine Use Disorder: Not Recommended as Monotherapy

Naltrexone alone is not recommended for treating methamphetamine use disorder, as current guidelines explicitly state that no pharmacologic treatment for stimulant dependence can be recommended for primary care use. 1 However, the combination of extended-release injectable naltrexone (380 mg every 3 weeks) plus oral extended-release bupropion (450 mg daily) has demonstrated efficacy and represents the only evidence-based pharmacotherapy option for this condition.

Current Guideline Position

The American Family Physician guidelines clearly state that despite continued research efforts, no pharmacologic treatment for stimulant (including methamphetamine) dependence can be recommended for use in the primary care setting as monotherapy. 1 Behavioral therapies remain the primary evidence-based treatment approach. 1

Evidence-Based Combination Therapy Regimen

Naltrexone-Bupropion Combination

The ADAPT-2 trial (2021) established that combination therapy is superior to placebo:

• Extended-release injectable naltrexone: 380 mg intramuscularly every 3 weeks 2
• Oral extended-release bupropion: 450 mg daily 2
• Treatment duration: 12 weeks minimum 2
• Response rate: 13.6% with combination therapy vs. 2.5% with placebo (treatment effect of 11.1 percentage points, P<0.001) 2

Extended Treatment Benefits

Continued treatment beyond 6 weeks provides additional benefit:

• Participants receiving the full 12 weeks showed a 27.1% increase in probability of testing methamphetamine-negative 3
• Stage 2 continuation (weeks 7-12) yielded an additional 9.2% improvement 3
• The cumulative 12-week benefit was 15.8% greater than placebo 3

Dosing Protocol (If Combination Therapy Used)

Pre-Treatment Requirements

Critical contraindication check: 4

• Patient must NOT be taking opioid analgesics
• Patient must NOT be on opioid agonist therapy (methadone, buprenorphine)
• Patient must be opioid-free for minimum 7-10 days for short-acting opioids 4
• Patients transitioning from buprenorphine or methadone may require up to 2 weeks opioid-free 4

Naltrexone Component

• Formulation: Extended-release injectable (Vivitrol) 380 mg 2
• Route: Intramuscular injection 2
• Frequency: Every 3 weeks (weeks 1,4,7,10) 2
• Monitoring: Baseline liver function tests and repeat every 3-6 months 1

Bupropion Component

• Formulation: Extended-release oral (Wellbutrin XL) 2
• Dose: 450 mg daily 2
• Administration: Once daily dosing 2

Safety Considerations

Common Adverse Events with Combination Therapy

• Gastrointestinal disorders 2
• Tremor 2
• Malaise 2
• Hyperhidrosis 2
• Anorexia 2
• Serious adverse events occurred in 3.6% of participants 2

Critical Warnings

Hepatotoxicity risk: Naltrexone has been associated with hepatic injury at supratherapeutic doses, requiring baseline and periodic liver function monitoring. 1

Precipitated withdrawal: If any occult opioid use exists, naltrexone will precipitate severe withdrawal symptoms. 4

Clinical Context and Limitations

Modest Efficacy

The absolute response rate remains low (13.6%) even with combination therapy, though significantly better than placebo. 2 This underscores that pharmacotherapy is only one component of comprehensive treatment.

Monotherapy Data

One older trial (2008) showed naltrexone 50 mg daily alone reduced amphetamine use compared to placebo, 5 but this predates current guidelines and the more robust ADAPT-2 combination therapy data. The guideline recommendation against monotherapy takes precedence. 1

Essential Adjunctive Treatment

Behavioral therapies are mandatory and have demonstrated effectiveness as the primary treatment modality. 1 Pharmacotherapy should never be used in isolation but only as part of a comprehensive treatment plan including:

• Relapse prevention therapy 5
• Medical management 6
• Community-based support groups 1
• Medication adherence monitoring 4

Practical Implementation

If pursuing combination therapy:

• Twice-weekly clinic visits for monitoring and support 6
• Urine drug screening twice weekly 2
• Observed dosing when feasible to ensure adherence 6
• Treatment duration of at least 12 weeks for optimal benefit 2, 3

Depression as Predictor

Early improvement in depressive symptoms (by week 4) with naltrexone-bupropion predicts better methamphetamine treatment response, explaining approximately 25% of the treatment effect. 7 This suggests monitoring mood symptoms may help identify treatment responders.